Cardiology Diagnostics Program
Cardiovascular Diseases
DiscoveryActive
Key Facts
About Aptus Biosciences
Aptus Biosciences is a private, pre-revenue diagnostics company focused on reinventing aptamer technology for clinical applications. The company is developing a platform of chemically modified DNA aptamers designed as high-specificity, high-affinity reagents for detecting disease biomarkers. Its initial pipeline targets major therapeutic areas including neurology, oncology, cardiology, and infectious diseases, with the goal of enabling earlier and more accurate diagnosis. As an early-stage venture, Aptus is likely seeking partnerships and investment to advance its programs from platform development into validated diagnostic assays.
View full company profileTherapeutic Areas
Other Cardiovascular Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Anti-platelet | Dawah Pharmaceuticals | Development |
| Autonomic Therapy Initiative (ATI) | BIOS Health | Pre-clinical |
| Cardiovascular Collaboration | Unnatural Products | Discovery |
| SBX 2000 | Stramsen Biotech | Early-stage Clinical |
| Not specified on provided pages | Cadila Pharmaceuticals | Commercial (World's First Claim) |
| Cardiovascular Biomarkers R&D | Firalis | Development |
| EPS222 | Eusol Biotech | Preclinical |